[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612744":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":26,"locations":32,"responsibleParty":52,"collaborators":10,"id":54,"slug":10,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":10,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"First Affiliated Hospital of Fujian Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"PegIFNα2b+Nucleoside analog",null,"The patients receive both PegIFNα2b and Nucleoside analog therapy.",[13],"Drug: PegIFNα2b+Nucleoside analog",{"label":15,"type":10,"description":16,"interventionNames":17},"PegIFNα2b+Nucleoside analog+Bacteroides fragilis+Branched-Chain Amino Acids","The patients received the concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids, supplemented to their ongoing combination therapy with PegIFNα2b and Nucleoside analog.",[18],"Drug: PegIFNα2b+Nucleoside analog+Bacteroides fragilis+Branched-Chain Amino Acids",[20,23],{"type":21,"name":9,"description":11,"armGroupLabels":22,"otherNames":10},"DRUG",[9],{"type":21,"name":15,"description":24,"armGroupLabels":25,"otherNames":10},"The patients received the concomitant administration of Bacteroides fragilis and BCAA, supplemented to their ongoing combination therapy with PegIFNα2b and Nucleoside analog.",[15],[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"JinShui Pan","CONTACT","0086+059187981658","zdy20221021@gmail.com",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"The First Affiliated Hospital of Fujian Medical University","RECRUITING","Fuzhou","Fujian","350005","China","CN",{"type":42,"coordinates":43},"Point",[44,45],119.30611,26.06139,{"lat":45,"lon":44},[48],{"name":49,"role":29,"phone":50,"phoneExt":10,"email":51},"Anpeng Wu","0086+059187981029","fjydfyjg@163.com",{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100612744",false,"NCT07257562","Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance","A Prospective Observational Study on the Effects of Concomitant Administration of Bacteroides Fragilis and Branched-Chain Amino Acids on HBsAg Clearance","Inclusion Criteria:\n\n\\- chronic hepatitis B patients\n\nExclusion Criteria:\n\n* patients with malignancies\n* patients with other liver diseases\n* pregnancy patients","ALL","18 Years",{"count":63,"type":64},40,"ESTIMATED","OBSERVATIONAL","The goal of this prospective observational study is to determine the effects of concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids on hepatitis B virus clearance. The primary question it aims to answer is whether this concomitant administration can promote HBV clearance.\n\nThe study will observe the HBV clearance rate in chronic hepatitis B patients who receive Bacteroides fragilis and BCAA as a supplement to their routine antiviral therapy. For comparison, researchers will compare the clearance rate in this group to that observed in a control group of chronic hepatitis B patients receiving a standard antiviral regimen based on PegIFNα2b and nucleoside analogs.",[68],"Chronic Hepatitis B",[70],"Hepatitis B","2025-12-01",{"date":73,"type":74},"2025-12-02","ACTUAL",{"date":76,"type":74},"2025-06-01",{"date":78,"type":64},"2026-12-01",{"name":5,"class":6},1]